Canopy Growth Reports Mixed Fiscal 2026 Results with Medical Cannabis Growth and Storz & Bickel Decline — Canopy Growth Corporation

Event summary

Canopy Growth reported a 10% increase in consolidated net revenue to $71.2M in Q4 FY2026, with a 27% growth in Canada medical cannabis and 68% in international markets.
Storz & Bickel revenue declined by 14% in Q4 FY2026 due to lapping strong prior-year sales and economic uncertainty.
The company recorded $67.1M in asset impairment and restructuring costs in FY2026, primarily related to Storz & Bickel.
Adjusted EBITDA loss improved by 32% in Q4 FY2026, with the company aiming for positive adjusted EBITDA in FY2027.
Canopy Growth completed the acquisition of MTL Cannabis and launched new products like Spectrum Reserve and DeeLish.

The big picture

Canopy Growth's fiscal 2026 results highlight a strategic pivot towards medical cannabis and international expansion, offset by challenges in the Storz & Bickel segment. The company's focus on cost reduction and product innovation aims to position it as a leader in the cannabis industry, particularly in Europe. The broader market dynamics, including regulatory shifts and economic uncertainty, will play a crucial role in Canopy Growth's ability to achieve its financial targets.

What we're watching

Market Expansion: How Canopy Growth's focus on international markets, particularly Europe, will impact its revenue growth and market share.
Cost Management: Whether the company's cost discipline and SG&A reductions can sustain profitability improvements in FY2027.
Product Innovation: The pace at which new product launches, such as Spectrum Reserve and DeeLish, can drive consumer engagement and revenue.